Fortis Healthcare Ltd. · NSE:FORTIS
Fortis Healthcare — Q1 FY26 Earnings Presentation
32 slides from Fortis Healthcare's earnings presentation, Aug 6, 2025
Slide 1: Fortis Healthcare Limited Earnings Presentation – Q1 FY26
FORTIS HEALTHCARE LIMITED EARNINGS PRESENTATION – Q1 FY26 August 06, 2025 1
Slide 2: Disclaimer
DISCLAIMER This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been pr
Slide 3: About Fortis Healthcare
About Fortis Healthcare National Capital Region ➢ FMRI, Gurugram ➢ FEHI, New Delhi 33 Healthcare Facilities ➢ Shalimar Bagh 1,978 ➢ Noida ➢ Vasant Kunj (O&M) ➢ Faridabad 5,700+ Operational Beds^ Punjab ➢ Manesar, Gurugram ➢ Mohali ➢ La Femme GK ➢ Ludhiana ➢ Def Col 6,800+ Doctors* 965 ➢ Ludhiana 2 ➢
Slide 4: Agenda
AGENDA 1. Clinical Excellence at Fortis 2. Performance Highlights • Earnings and Financial Summary – Q1FY26 3. Performance Review - Hospital Business 4. Performance Review - Diagnostics Business 5. Appendix 4
Slide 5: Clinical Excellence at Fortis
CLINICAL EXCELLENCE AT FORTIS KEY HIGHLIGHTS 5
Slide 6: Clinical Excellence
CLINICAL EXCELLENCE • Fortis Escorts, Okhla Road, New Delhi, performed India’s first combined robot- assisted heart bypass (CABG) and breast cancer surgery (modified radical mastectomy) in a single 11-hour operative procedure on a 72-year-old patient. • Fortis Hospital, Gurugram, successfully remove
Slide 7: Augmenting Medical Programs
AUGMENTING MEDICAL PROGRAMS ➢ Fortis Hospitals at Mohali and BG Road, installed second Da Vinci Xi soft tissue robots. ➢ Fortis Hospital, Ludhiana, launched its newly upgraded Radiology Department, equipped with advanced medical technology including MRI 3.0 Tesla, 128-slice CT, PET CT, digital mammo
Slide 8: Q1FY26 Performance Highlights
Q1FY26 PERFORMANCE HIGHLIGHTS 8
Slide 9: Q1FY26 Snapshot
Q1FY26 SNAPSHOT Consolidated Revenue Consolidated Op EBITDA Consolidated PBT1 2,167 Crores 491 Crores 338 Crores (22.6% Margin) 16.6% 43.2% 47.0% Consolidated PAT1 Net Debt / (Cash)3 Net Debt to EBITDA2,3 254 Crores 1,869 Crores 0.92x vs 0.22x 46.2% 1. Excluding exceptional items 2. Basis Q1FY26 ann
Slide 10: Recent Key Updates
Recent Key Updates O&M Agreement with Gleneagles Consummation of Shrimann Hospital transaction Jul’25 : FHL entered into an Operation and Jul’25: Fortis through its wholly owned Maintenance Services (“O&M Services”) subsidiary consummated the acquisition agreement with GHIPL. Under the of Shrimann S
Slide 11: Q1FY26 Snapshot
Q1FY26 SNAPSHOT ➢ Hospital business revenues grew 18.6% to INR 1,838 Cr versus INR 1,549 Cr in Q1FY25 ➢ Hospital Business Operating EBITDA stood at INR 406 Cr, up 41.4%; while operating EBITDA margin was at 22.1% versus 18.5% in Q1FY25 ➢ Q1FY26 hospital business ARPOB was at INR 2.65 Cr per annum vs
Slide 12: Consolidated Earnings Summary – Q1FY26
CONSOLIDATED EARNINGS SUMMARY – Q1FY26 All figures in INR Cr Revenue Op EBITDA & Margin 2,167 2,007 491 435 343 1,859 22.6% 21.7% 18.4% Q1FY25 Q4FY25 Q1FY26 Q1FY25 Q4FY25 Q1FY26 Up 16.6% Up 43.2% PBT before Exceptional Items PAT* 338 290 242 254 230 174 Q1FY25 Q4FY25 Q1FY26 Q1FY25 Q4FY25 Q1FY26 Up 4
Slide 13: Consolidated Earnings Summary
CONSOLIDATED EARNINGS SUMMARY All figures in INR Cr Consolidated Revenue 2,167 1,988 2,007 1,928 1,859 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Op EBITDA Margin Op EBITDA PBT (before Exceptional items) 22.6% 21.9% 21.7% 18.4% 19.4% 491 435 435 375 343 321 338 290 230 256 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26
Slide 14: Hospital Business Highlights
Q1FY26 HOSPITAL BUSINESS HIGHLIGHTS Key Performance Indicators • Occupancy was at 69%, compared to 67% in Q1FY25. Overall Occupancy Occupied beds increased to 2,928 compared to 2,715 in Q1FY25, a 69% 69% 67% growth of 7.8%. • Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac
Slide 15: Diagnostic Business Highlights
Q1FY26 DIAGNOSTIC BUSINESS HIGHLIGHTS • Agilus gross revenues grew 7.4% to INR 368.8 Cr in Q1FY26 versus INR 343.5 Cr in Q1FY25 • Operating EBITDA stood at INR 84.7 Cr in Q1FY26 versus INR 55.4 Cr in Q1FY25 • Operating EBITDA Margin (basis gross revenues) stood at 23.0% versus 16.1% in Q1FY25. Exclu
Slide 16: Operating Performance – Hospital Business
OPERATING PERFORMANCE HOSPITAL BUSINESS Hospital Business Particulars (INR Cr) Q1FY25 Q4FY25 Q1FY26 Operating Revenue 1,549 1,701 1,838 Revenue Growth vs LY 14.4% 14.2% 18.6% Reported EBITDA 295 384 415 EBITDA growth vs LY 41.9% 13.2% 40.5% Margin 19.1% 22.6% 22.6% Adj: Other Income^ 8 12 9 Operatin
Slide 17: Operating Performance – Diagnostic Business
OPERATING PERFORMANCE DIAGNOSTIC BUSINESS Diagnostic Business Particulars (INR Cr) Q1FY25 Q4FY25 Q1FY26 Operating Revenue 344 348 369 Revenue Growth vs LY 0.2% 3.0% 7.4% Reported EBITDA 60 71 91 EBITDA growth vs LY (16.8%) 37.9% 51.4% Margin 17.6% 20.4% 24.7% Adj: Other Income incl FX 5 9 7 Operatin
Slide 18: Balance Sheet (Consolidated)
BALANCE SHEET (CONSOLIDATED) June 30, 2025 Balance Sheet (INR Cr) Jun 30, 2024 Mar 31, 2025 Jun 30, 2025 Shareholder’s Equity 8,615 9,169 9,435 Debt 866 2,196 2,355 Lease Liabilities (Ind AS 116)* 298 280 274 Total Capital Employed 9,779 11,645 12,064 Net Fixed Assets (including intangibles & CWIP)
Slide 19: Performance Review – Hospitals Business
PERFORMANCE REVIEW HOSPITALS BUSINESS 19
Slide 20: Specialty Mix
SPECIALTY MIX Q1FY25 Q1FY26 Other Operating Other Operating Revenue, 1.8% Revenue, 1.9% OPD, 13.6% Cardiac, Cardiac, OPD, 13.9% 16.9% 17.3% Other IPD, Other IPD, 15.6% Ortho, 9.9% Ortho, 9.9% 15.4% Renal, 7.0% Renal, 6.9% Gynae, 3.3% Gynae, 3.1% Pulmo, 2.5% Pulmo, 2.5% Neuro, 8.1% Neuro, 8.8% Onco,
Slide 21: Payor Mix
PAYOR MIX Q1FY25 Q1FY26 ESI, 0.0% ESI, 0.1% TPAs, 36.1% TPAs, 37.1% Cash : Cash : Domestic, Domestic, 34.3% 33.6% Pvt Corps, 1.0% Pvt Corps, 1.0% International , International , Govt & 7.8% 7.9% Govt & PSUs, 8.5% CGHS, 4.7% ECHS, 7.7% PSUs, 8.7% CGHS, 4.3% ECHS, 7.3% 21
Slide 22: Hospital Business Performance – Q1FY26
HOSPITAL BUSINESS PERFORMANCE – Q1FY26 All the key healthcare facilities continue to witness a YoY and QoQ upward momentum in revenues Revenue Q1FY25 Q1FY26 286 All figures in INR Cr. 233 233 198 177 141 157 145 153 144 134 116 120 128 82 96 58 72 55 66 FMRI Mohali Shalimar Bagh Noida BG Road FEHI M
Slide 23: Hospital Margin Matrix
HOSPITAL MARGIN MATRIX EBITDA No of Facilities Revenue Contribution Operational beds ARPOB (INR Cr) Occupancy >20% 11 75.2% 2,888 2.83 71% 15% - 20% 3 12.4% 595 2.23 74% Q1FY26 10% - 15% 1 0.6% 46 1.87 51% <10% 6^ 10.7% 714 2.02 58% ^ Note: <10% EBITDA Margin facilities include Ludhiana 2 (commissio
Slide 24: Beds Expansion Update
BEDS EXPANSION UPDATE 24
Slide 25: Key Ongoing Expansion Projects
Key Ongoing Expansion Projects Manesar Facility (~300 Beds)* – ~180 Bed Capacity added till July’25 (96 beds operationalized) Faridabad New Tower (50 Beds) – Expected operationalization H1FY26 Remaining Capacity Addition: Q3FY26 Noida New Tower (~150 Beds) – ~60 Beds operationalized: Q1FY26 FMRI New
Slide 26: Performance Review – Diagnostics Business
PERFORMANCE REVIEW DIAGNOSTICS BUSINESS 26
Slide 27: Diagnostics Business
DIAGNOSTICS BUSINESS • During Q1 FY26, Agilus conducted 10.13 Mn tests, versus 9.57 Mn in Q1 FY25, representing a growth of 5.8%. • Agilus added 160+ Customer touchpoints* to its network in Q1 FY26. • Agilus’ B2C: B2B revenue mix stood at 51:49 in the quarter vs 52:48 in Q1 FY25. • Operating EBITDA
Slide 28: Quarterly Revenue Mix
QUARTERLY REVENUE MIX Geographic mix Product Mix Segment Mix International 4% Wellness 12% B2C, Q1FY26 North 51% South 31% 31% Routine B2B, Specialised 54% 49% 34% East 13% West 20% International 3% Wellness 12% North Q1FY25 32% B2C, South 52% 30% Routine B2B, 52% 48% Specialised 36% East West 14% 2
Slide 29: Quarterly Key Performance Metrics
QUARTERLY KEY PERFORMANCE METRICS Test (mn) Avg. Realization per test (INR) No of Patients (mn) Avg. Realization per patient (INR) 4.50 900 10.6 368 370 890 10.4 4.40 890 10.2 365 4.30 880 10 365 363 4.20 869 878 9.8 360 870 9.6 4.10 357 357 355 860 9.4 4.00 9.2 353 854 850 350 3.90 9 846 840 3.80 8
Slide 30: Appendix
| x la Z uu Oo. oO. <x
Slide 31: Group Consolidated P&L – Q1FY26
GROUP CONSOLIDATED P&L – Q1FY26 Particulars ( INR Cr) Q1FY25 Q4FY25 Q1FY26 Revenue from operations 1,858.9 2,007.2 2,166.7 Other income 13.0 19.8 15.4 Total income 1,871.9 2,027.0 2,182.1 Expenses 1,516.4 1,571.7 1,676.0 EBITDA* 355.5 455.3 506.1 Margin 19.1% 22.7% 23.4% Finance costs 35.3 67.6 69.6
Slide 32: Thank You
THANK YOU 32